Expansion Opportunities Dermapharm has a growing international footprint with multiple production, development, and distribution sites in Europe and the United States, suggesting potential for new market entry partnerships, contract manufacturing, and co-development deals in additional regions.

Strong Brand Portfolio With approximately 1,300 marketing authorisations and a focus on branded pharmaceuticals, there are opportunities to cross-sell, co-market, or license novel formulations, device integrations, or complementary health products to expand Dermapharm's market reach.

Acquisition-Driven Growth A history of acquisitions including Arkopharma and Euromed demonstrates openness to strategic partnerships and M&A; explore avenues for distribution rights, technology licensing, and joint ventures to accelerate product diversification.

Herbal and Plant-Based Upside Access to Euromed S.A. herbal extracts and C³ Group synthetic cannabinoids positions Dermapharm to partner on botanical and cannabinoid-based formulations, nutraceuticals, and over-the-counter solutions in Europe and beyond.

Parallel Import Channel Axicorp brand presence in the parallel import market indicates potential for optimized cross-border distribution partnerships, grey-market strategies, and regulatory-compliant channel collaborations to broaden reach and improve margins.